1. Home
  2. PLBL vs WGS Comparison

PLBL vs WGS Comparison

Compare PLBL & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLBL

Polibeli Group Ltd Class A Ordinary Shares

N/A

Current Price

$8.65

Market Cap

3.0B

Sector

N/A

ML Signal

N/A

Logo GeneDx Holdings Corp.

WGS

GeneDx Holdings Corp.

HOLD

Current Price

$76.90

Market Cap

2.6B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLBL
WGS
Founded
2021
2017
Country
Indonesia
United States
Employees
N/A
1300
Industry
Retail: Computer Software & Peripheral Equipment
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.6B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PLBL
WGS
Price
$8.65
$76.90
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$140.71
AVG Volume (30 Days)
2.8K
722.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$29.98
Revenue Next Year
N/A
$24.85
P/E Ratio
N/A
$1,251.58
Revenue Growth
N/A
N/A
52 Week Low
$5.60
$55.17
52 Week High
$13.48
$170.87

Technical Indicators

Market Signals
Indicator
PLBL
WGS
Relative Strength Index (RSI) 51.85 39.55
Support Level $7.36 $68.55
Resistance Level $9.50 $95.94
Average True Range (ATR) 0.60 5.58
MACD 0.17 0.83
Stochastic Oscillator 69.45 32.05

Price Performance

Historical Comparison
PLBL
WGS

About PLBL Polibeli Group Ltd Class A Ordinary Shares

Polibeli Group Ltd is engaged in goods trading and others to promote the circulation of goods with a focus on making trading easier. The products offered by the company include consumer electronic accessories, household appliances, skincare products, oral-care products, cosmetics products, toys and game products, and health-care products. Geographically, the company derives the majority of its revenue from Japan.

About WGS GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: